TAM, as a selective estrogen receptor (ER) modulator, has been used as the first-line treatment for ER-positive breast cancer for many years, but its effectiveness is limited as most advanced breast cancer eventually recur with acquired resistance despite initial responsiveness to TAM [35]. Here, ESR1 is linked to breast carcinoma.